021-51111890
购物车（）
sales@molnova.cn
Bevacizumab
CAS No. 216974-75-3
Bevacizumab ( —— )
产品货号. M22136 CAS No. 216974-75-3
Ipilimumab (抗 CTLA-4) 是一种针对细胞表面抗原 CTLA-4 的免疫调节性单克隆抗体，也是一种免疫检查点抑制剂。 Bevacizumab 是一种人源化单克隆抗体，以高亲和力特异性结合所有 VEGF-A 亚型。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥3216 | 有现货 |
|
| 10MG | ￥4334 | 有现货 |
|
| 25MG | ￥7007 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Bevacizumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Ipilimumab (抗 CTLA-4) 是一种针对细胞表面抗原 CTLA-4 的免疫调节性单克隆抗体，也是一种免疫检查点抑制剂。 Bevacizumab 是一种人源化单克隆抗体，以高亲和力特异性结合所有 VEGF-A 亚型。
-
产品描述Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
-
体外实验Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
-
体内实验It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?同义词——通路Angiogenesis靶点VEGFR受体VEGFR研究领域——适应症——
化学信息
-
CAS Number216974-75-3
-
分子量149 kDa
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
产品手册
关联产品
-
PAN-90806
PAN-90806 (CP-547632, CP547632) 是一种高效、ATP 竞争性、口服活性的 VEGFR-2 抑制剂，可阻断 VEGFR-2 激酶自身磷酸化 (IC50=11 nM) 和 VEGF 诱导的 VEGFR-2 磷酸化 (IC50=5)纳米）。
-
Semaxinib
Semaxanib (SU5416) 是一种有效的选择性 VEGFR(Flk-1/KDR) 抑制剂。
-
TIE-2/VEGFR-2 kinase...
TIE-2/VEGFR-2 kinase-IN-5 是一个抗血管生成剂。TIE-2/VEGFR-2 kinase-IN-5 也是一种有效的 TIE-2 和 VEGFR-2 酪氨酸激酶受体抑制剂， pIC50 值分别为 7.78 nM 和 8.11 nM。TIE-2/VEGFR-2 kinase-IN-5 可用于血管生成的研究。
